Advertisement

Topics

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

13:41 EDT 22 Sep 2016 | SCRIP

UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid...

      

Related Stories

 

Original Article: UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

NEXT ARTICLE

More From BioPortfolio on "UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense"

Quick Search
Advertisement
 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...